[go: up one dir, main page]

JO3067B1 - بيرميدينات بيرازولو امينو كمثبطات ل fak - Google Patents

بيرميدينات بيرازولو امينو كمثبطات ل fak

Info

Publication number
JO3067B1
JO3067B1 JOP/2009/0395A JOP20090395A JO3067B1 JO 3067 B1 JO3067 B1 JO 3067B1 JO P20090395 A JOP20090395 A JO P20090395A JO 3067 B1 JO3067 B1 JO 3067B1
Authority
JO
Jordan
Prior art keywords
fak
inhibitors
amino pyrimidines
pyrimidine amino
pyrimidine
Prior art date
Application number
JOP/2009/0395A
Other languages
English (en)
Inventor
H Faitg Thomas
Leroy Adams Jerry
W Johnson Neil
Lin Hong
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42132177&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3067(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Application granted granted Critical
Publication of JO3067B1 publication Critical patent/JO3067B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • G01N33/5752—

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pyridine Compounds (AREA)
  • Molecular Biology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

يتعلق الاختراع الحالي لمركب الصياغة(I): (I) أو ملح مقبول صيدلانيا لهم, حيث R1, R2, R3, R11, R12, R13, Q, Z وp هم كما وصف هنا. مركبات الاختراع الحالي تكون مفيدة لعلاج السرطانات.
JOP/2009/0395A 2008-10-27 2009-10-25 بيرميدينات بيرازولو امينو كمثبطات ل fak JO3067B1 (ar)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10856808P 2008-10-27 2008-10-27
US17851709P 2009-05-15 2009-05-15
US24243209P 2009-09-15 2009-09-15

Publications (1)

Publication Number Publication Date
JO3067B1 true JO3067B1 (ar) 2017-03-15

Family

ID=42132177

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2009/0395A JO3067B1 (ar) 2008-10-27 2009-10-25 بيرميدينات بيرازولو امينو كمثبطات ل fak

Country Status (35)

Country Link
US (6) US20100113475A1 (ar)
EP (1) EP2421537B1 (ar)
JP (1) JP5642689B2 (ar)
KR (1) KR101512217B1 (ar)
CN (1) CN102264371B (ar)
AR (1) AR073993A1 (ar)
AU (1) AU2009320144B2 (ar)
BR (1) BRPI0920053B8 (ar)
CA (1) CA2741760C (ar)
CL (1) CL2011000933A1 (ar)
CO (1) CO6361929A2 (ar)
CR (1) CR20110264A (ar)
CY (1) CY1116399T1 (ar)
DK (1) DK2421537T3 (ar)
DO (1) DOP2011000113A (ar)
EA (1) EA021927B1 (ar)
ES (1) ES2539835T3 (ar)
HR (1) HRP20150531T1 (ar)
IL (1) IL212444A (ar)
JO (1) JO3067B1 (ar)
MA (1) MA32727B1 (ar)
MX (1) MX2011004369A (ar)
MY (1) MY161890A (ar)
NZ (1) NZ592477A (ar)
PE (1) PE20110941A1 (ar)
PL (1) PL2421537T3 (ar)
PT (1) PT2421537E (ar)
RS (1) RS54045B1 (ar)
SG (1) SG195608A1 (ar)
SI (1) SI2421537T1 (ar)
SM (1) SMT201500157B (ar)
TW (1) TWI454467B (ar)
UY (1) UY32200A (ar)
WO (1) WO2010062578A1 (ar)
ZA (1) ZA201102892B (ar)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8338441B2 (en) 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
JP2014503589A (ja) * 2011-01-26 2014-02-13 グラクソスミスクライン、インテレクチュアル、プロパティー、リミテッド 組合せ
DK2675794T3 (da) 2011-02-17 2019-05-06 Cancer Therapeutics Crc Pty Ltd Selektive fak-inhibitorer
EP2675793B1 (en) 2011-02-17 2018-08-08 Cancer Therapeutics Crc Pty Limited Fak inhibitors
BR112013034066A2 (pt) * 2011-06-28 2017-02-07 Glaxosmithkline Intellectual Property (No 2) Ltd método de administração e tratamento
WO2015054477A1 (en) 2013-10-09 2015-04-16 The General Hospital Corporation Methods of diagnosing and treating b cell acute lymphoblastic leukemia
MX389683B (es) 2015-06-29 2025-03-20 Verastem Inc Composiciones terapeuticas, combinaciones y metodos de uso
CN108948019B (zh) * 2017-05-18 2022-07-08 广东东阳光药业有限公司 黏着斑激酶抑制剂及其用途
WO2019117813A1 (en) * 2017-12-15 2019-06-20 National University Of Singapore Focal adhesion kinase targeted therapeutics for the treatment of glaucoma and fibrosis
EP3765085A1 (en) 2018-03-12 2021-01-20 Université de Paris Use of caloric restriction mimetics for potentiating chemo-immunotherapy for the treatment of cancers
CN108912095B (zh) * 2018-08-09 2019-08-20 广州安岩仁医药科技有限公司 苯并咪唑类化合物及其制备方法和应用
WO2020069117A1 (en) * 2018-09-27 2020-04-02 Dana-Farber Cancer Institute, Inc. Degradation of fak or fak and alk by conjugation of fak and alk inhibitors with e3 ligase ligands and methods of use
US12194040B2 (en) * 2018-12-27 2025-01-14 Hinova Pharmaceuticals Inc. FAK inhibitor and drug combination thereof
MX2021011209A (es) * 2019-03-15 2022-01-19 Massachusetts Gen Hospital Novedosos inhibidores de molécula pequeña de factores de transcripción tead.
CN113387947B (zh) * 2021-07-12 2022-07-01 中国科学院成都生物研究所 调节雌激素受体合成活性的吡唑并吡啶衍生物
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
TW202530228A (zh) 2023-10-12 2025-08-01 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US166139A (en) * 1875-07-27 Improvement in dental pluggers
WO2000014105A1 (en) 1998-09-08 2000-03-16 Agouron Pharmaceuticals, Inc. Modifications of the vegf receptor-2 protein and methods of use
US7102009B2 (en) * 2001-01-12 2006-09-05 Amgen Inc. Substituted amine derivatives and methods of use
PT1660458E (pt) * 2003-08-15 2012-04-27 Novartis Ag 2,4-pirimidinodiaminas úteis no tratamento de doenças neoplásicas, desordens inflamatórias e do sistema imunitário
GB0419161D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
GB0419160D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
EP1746096A1 (en) * 2005-07-15 2007-01-24 4Sc Ag 2-Arylbenzothiazole analogues and uses thereof in the treatment of cancer
CN101679264A (zh) * 2007-03-16 2010-03-24 斯克里普斯研究学院 粘着斑激酶抑制剂
EP2249650A4 (en) * 2008-02-19 2012-01-11 Glaxosmithkline Llc ANILINOPYRIDINE AS A FAK HEMMER
US8569298B2 (en) * 2008-06-17 2013-10-29 Astrazeneca Ab Pyridine compounds

Also Published As

Publication number Publication date
JP2012506876A (ja) 2012-03-22
RS54045B1 (sr) 2015-10-30
CR20110264A (es) 2011-10-04
PT2421537E (pt) 2015-07-03
NZ592477A (en) 2013-01-25
CN102264371B (zh) 2013-10-02
IL212444A0 (en) 2011-06-30
CO6361929A2 (es) 2012-01-20
PE20110941A1 (es) 2012-02-08
CA2741760A1 (en) 2010-06-03
WO2010062578A1 (en) 2010-06-03
PL2421537T3 (pl) 2015-08-31
SG195608A1 (en) 2013-12-30
AR073993A1 (es) 2010-12-15
AU2009320144B2 (en) 2013-11-21
SMT201500157B (it) 2015-09-07
CA2741760C (en) 2016-02-23
CY1116399T1 (el) 2017-02-08
EA021927B1 (ru) 2015-09-30
US20140107131A1 (en) 2014-04-17
SI2421537T1 (sl) 2015-06-30
US20150265589A1 (en) 2015-09-24
BRPI0920053B1 (pt) 2019-11-26
JP5642689B2 (ja) 2014-12-17
EP2421537A4 (en) 2012-06-13
TW201028394A (en) 2010-08-01
US20160095841A1 (en) 2016-04-07
EA201170617A1 (ru) 2011-12-30
TWI454467B (zh) 2014-10-01
KR101512217B1 (ko) 2015-04-15
AU2009320144A1 (en) 2010-06-03
CL2011000933A1 (es) 2011-10-21
DK2421537T3 (da) 2015-06-22
BRPI0920053A2 (pt) 2015-12-15
ES2539835T3 (es) 2015-07-06
UY32200A (es) 2010-05-31
CN102264371A (zh) 2011-11-30
EP2421537A1 (en) 2012-02-29
US20100113475A1 (en) 2010-05-06
BRPI0920053B8 (pt) 2021-05-25
DOP2011000113A (es) 2011-07-15
MY161890A (en) 2017-05-15
US20110269774A1 (en) 2011-11-03
ZA201102892B (en) 2012-02-29
HK1161680A1 (en) 2012-08-03
MX2011004369A (es) 2011-05-25
US9012479B2 (en) 2015-04-21
IL212444A (en) 2015-11-30
KR20110080172A (ko) 2011-07-12
HRP20150531T1 (hr) 2015-06-19
MA32727B1 (ar) 2011-10-02
US20110207743A1 (en) 2011-08-25
EP2421537B1 (en) 2015-04-08
US9446034B2 (en) 2016-09-20

Similar Documents

Publication Publication Date Title
JO3067B1 (ar) بيرميدينات بيرازولو امينو كمثبطات ل fak
EA201100580A1 (ru) Имидазопиридазинкарбонитрилы, используемые в качестве ингибиторов киназы
TN2011000404A1 (en) Fused pyrimidines
PH12015501585A1 (en) Manufacturing process for pyrimidine derivatives
EA201000113A1 (ru) Пиразольные соединения
ATE542813T1 (de) 6-substituierte 2- heterocyclylaminopyrazinverbindungen als chk-1- inhibitoren
TN2011000293A1 (en) Protein kinase inhibitors
JO3007B1 (ar) مركبات و تركيبات كمثبطات كيناز بروتين
EA200970207A1 (ru) Соединения пиридо[2,3-d]пиримидинона и их применение в качестве pi3 ингибиторов
MY160454A (en) Oxazole substituted indazoles as pi3-kinase inhibitors
TN2010000070A1 (en) Fused bicyclic pyrimidines
TW200626610A (en) Analogs of 17-hydroxywortmannin as PI3K inhibitors
MD20140047A2 (ro) Inhibitori ai protein kinazei
EA201290632A1 (ru) Производные бетулина
GEP20135957B (en) Heterocyclic compound and usage thereof
PH12014500373A1 (en) Amino quinazolines as kinase inhibitors
EA201170154A1 (ru) Производные пиридинопиридинонов, способ их получения и применение в терапии
MX2012006805A (es) Indolil-piperidinil bencilaminas como inhibidores de beta-triptasa.
MA32142B1 (ar) شكل بلوري لمشتقات الفينيل امينو بيريميدين
EA201190293A1 (ru) Пролекарства триптолида
EA201001348A1 (ru) Пирролопиримидинкарбоксамиды
EA201200322A1 (ru) Метилпирролопиримидинкарбоксамиды
TNSN06260A1 (en) Process for the preparation of tryptase inhibitors
MX2009004625A (es) Derivados de 3-amino-pirazol-4-carboxamida utiles como inhibidores de proteina cinasas.
EA201170461A1 (ru) Арилсульфонамидные аминосоединения и их применение в качестве лигандов 5-ht